Merck Canada Sues To Block Mylan's Generic Singulair

Law360, New York (January 3, 2012, 1:15 PM EST) -- Merck Canada Inc. on Thursday sued Mylan Pharmaceuticals Inc. in New Jersey federal court for allegedly infringing a Merck patent when it sought U.S. Food and Drug Administration approval for a generic version of the asthma treatment Singulair.

The plaintiffs — Merck Canada, Merck Frosst Canada & Co. and Merck Sharp & Dohme Pharmaceuticals — say Mylan alerted them in a Nov. 15 letter that it had lodged an abbreviated new drug application seeking a green light to make and sell its generic.

Mylan also informed...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.